Exercise feasibility: Relative dose intensity of exercise
The actual dose relative to the prescribed minimum dose
Exercise feasibility: Early termination of exercise sessions
Termination of an exercise session before the prescribed exercises have been performed
Exercise feasibility: Exercise intervention interruptions
Incidence of exercise intervention disruptions, defined as a period of ≥ 7 days without an attended exercise session
Exercise feasibility: Permanent discontinuation
Incidence of permanent withdrawal from the intervention before intervention period has ended.
Body composition and anthropometrics: Total lean mass
Changes in total lean mass, assessed by dual energy x-ray absorptiometry (DXA)
Body composition and anthropometrics: Appendicular lean mass
Changes in appendicular lean mass, assessed by DXA
Body composition and anthropometrics: Total fat mass
Changes in total fat mass, assessed by DXA
Body composition and anthropometrics: Fat percentage
Changes in fat percentage, assessed by DXA
Body composition and anthropometrics: Bone mineral density
Changes in bone mineral density, assessed by DXA
Body composition and anthropometrics: Muscle thickness
Changes in thickness of the vastus lateralis, assessed by ultrasound
Body composition and anthropometrics: Skeletal muscle index
Changes in skeletal muscle index, assessed by diagnostic CT scans
Body composition and anthropometrics: Skeletal muscle attenuation
Changes in skeletal muscle attenuation, assessed by diagnostic CT scans
Body composition and anthropometrics: Adipose tissue index
Changes in adipose tissue index, assessed by diagnostic CT scans
Body composition and anthropometrics: Body mass
Changes in body mass
Body composition and anthropometrics: Body mass index
Changes in body mass index
Body composition and anthropometrics: Hip circumference
Changes in hip circumference
Body composition and anthropometrics: Waist circumference
Changes in waist circumference
Muscle strength: Leg press maximal muscle strenght
Changes in leg press one repetition maximum (1RM)
Muscle strength: Chest press maximal muscle strenght
Changes in chest press 1RM
Muscle strength: Hand grip strenght
Changes in hand grip strength, assessed using a dynamometer
Functional performance: Habituel gait speed
Changes in habitual gait speed
Functional performance: Maximal gait speed
Changes in maximal gait speed
Functional performance: Sit-to-stand
Changes in sit-to-stand power.
Functional performance: Stair climb
Changes in stair climbing power
Resting metabolic rate
Changes in resting metabolic rate
Blood pressure: Systolic blood pressure
Changes in systolic blood pressure
Blood pressure: Diastolic blood pressure
Changes in diastolic blood pressure
Heart rate
Changes in resting heart rate
1 and 2-years cancer-specific survival
Proportion of patients who have not died from gastroesophageal cancer 1 and 2 years after randomization
1 and 2-years over-all survival
Proportion of patients who have not died 1 and 2 years after randomization
Progression-free survival
Time to progression
Treatment tolerance: Hospitalization
Unscheduled hospitalization
Treatment tolerance: Relative dose intensity
Treatment tolerance assessed by the delivery of chemotherapy (relative dose intensity)
Treatment tolerance: Number of series recieved
Treatment tolerance assessed by the delivery of chemotherapy (number of series recieved)
Treatment tolerance: Tolerated dose
Treatment tolerance assessed by the delivery of chemotherapy (dose reduction)
Treatment tolerance: Permanent discontinuation of the treatment
Treatment tolerance assessed by the delivery of chemotherapy (permanent discontinuation of the treatment)
Treatment effect: Response to chemotherapy
Response to chemotherapy assessed by Response Evaluation Criteria in Solid Tumors 1.1 (complete response, partiel response, stable disease, progressive disease)
Health-related quality of life: Physical well-being
Changes in patient-reported physical well-being assessed using the Functional Assessment of Cancer Therapy - Esophagus (FACT-E) (scale-scoring 0-28, the higher the score the better quality of life)
Health-related quality of life: Social well-being
Changes in patient-reported social well-being assessed using FACT-E (scale-scoring 0-28, the higher the score the better quality of life)
Health-related quality of life: Emotional well-being
Changes in patient-reported social well-being assessed using FACT-E (scale-scoring 0-24, the higher the score the better quality of life)
Health-related quality of life: Functional well-being
Changes in patient-reported functional well-being assessed using FACT-E (scale-scoring 0-28, the higher the score the better quality of life)
Health-related quality of life: gastroesophageal cancer specific
Changes in patient-reported gastroesophageal cancer specific well-being assessed using FACT-E (scale-scoring 0-68, the higher the score the better quality of life)
Health-related quality of life: cancer cachexia specific
Changes in patient-reported cancer cachexia specific well-being assessed using Functional Assessment of Cancer Therapy - Cancer Cachexia (scale-scoring 0-48, the higher the score the better quality of life)
Depression
Changes in patient-reported depression, assessed using the Hospital Anxiety and Depression Scale (HADS) (scale scoring: 0-21, the higher the score the worse the condition)
Anxiety
Changes in patient-reported anxiety, assessed using the HADS (scale scoring: 0-21, the higher the score the worse the condition)
Self-reported physical activity: Walking
Changes in patient-reported weekly duration of walking, assessed using the International Physical Activity Questionnaire (IPAQ)
Self-reported physical activity: Moderate intensity physical activity (PA)
Changes in patient-reported weekly duration of moderate intensity PA, assessed using the IPAQ
Self-reported physical activity: Vigorous intensity PA
Changes in patient-reported weekly duration of vigorous intensity PA, assessed using the IPAQ
Self-reported physical activity: Total PA
Changes in patient-reported weekly duration of total PA, assessed using the IPAQ (Expressed as metabolic equivalent (MET)-min per week: MET level x minutes of activity x events per week)
Self-reported physical activity: Sitting time
Changes in patient-reported weekly duration of sitting time, assessed using the IPAQ
Self-reported screening of sarcopenia
Changes in patient-reported signs of sarcopenia, assessed using The Strength, assistance in walking, rise from a chair, climb stairs, and falls (SARC-F) questionnaire (scale scoring: 0-10, the higher the score the better the condition)
Self-reported three-days dietary records
Changes in patient-reported three-day record of dietary intake assessed using questionnaries.
Patient-reported symptomatic adverse events
Patient-reported symptomatic adverse events, assessed using the using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)